Success Metrics

Completion Rate
0%(0/4)
Active Trials
1(17%)
Terminated
4(67%)

Phase Distribution

Ph phase_1
3
50%
Ph phase_2
2
33%
Ph phase_3
1
17%

Phase Distribution

3

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 5 finished

Non-Completion Rate

100.0%

5 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Terminated(5)

Detailed Status

Terminated4
Active, not recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (50.0%)
Phase 22 (33.3%)
Phase 31 (16.7%)

Trials by Status

active_not_recruiting117%
terminated467%
withdrawn117%

Recent Activity

1 active trials
Showing 5 of 6
terminatedphase_3

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

NCT04266301
active_not_recruitingphase_2

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

NCT05201066
terminatedphase_1

Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.

NCT04623216
terminatedphase_2

A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants

NCT04812548
terminatedphase_1

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients

NCT04097821
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04266301Phase 3

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

Terminated
NCT05201066Phase 2

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Active Not Recruiting
NCT04623216Phase 1

Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation.

Terminated
NCT04812548Phase 2

A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants

Terminated
NCT04097821Phase 1

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients

Terminated
NCT05367401Phase 1

A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6